Page last updated: 2024-12-10
7-deoxy-13-dihydroadriamycinone
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
7-deoxy-13-dihydroadriamycinone: a metabolite of epidoxorubicin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 3081104 |
| MeSH ID | M0201966 |
Synonyms (13)
| Synonym |
|---|
| 7-deoxydoxorubicinolone |
| 7-deoxy-13-dihydroadriamycinone |
| 5,12-naphthacenedione, 8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy- |
| 116455-20-0 |
| 8-(1,2-dihydroxyethyl)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione |
| aglycone c |
| 9-(1,2-dihydroxyethyl)-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione |
| FT-0665798 |
| J-012035 |
| 8-(1,2-dihydroxyethyl)-6,8,11-trihydroxy-1-methoxy-9,10-dihydro-7h-tet racene-5,12-dione |
| 7-deoxy doxorubicinol aglycone |
| 8-(1,2-dihydroxyethyl)-6,8,11-trihydroxy-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione |
| DTXSID50863400 |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Pharmacokinetic studies between SB and SAB showed modest differences." | ( Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer. Ahn-Jarvis, JH; Clinton, SK; Cruz-Cano, R; Grainger, EM; Lee, ML; Lesinski, GB; Riedl, KM; Schwartz, SJ; Vodovotz, Y; Young, GS, 2015) | 0.42 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " The primary objective was to investigate isoflavone bioavailability and metabolite profile." | ( Isoflavone pharmacokinetics and metabolism after consumption of a standardized soy and soy-almond bread in men with asymptomatic prostate cancer. Ahn-Jarvis, JH; Clinton, SK; Cruz-Cano, R; Grainger, EM; Lee, ML; Lesinski, GB; Riedl, KM; Schwartz, SJ; Vodovotz, Y; Young, GS, 2015) | 0.42 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, measuring the plasma concentration of doxorubicin and its metabolites is important to study the dosing regimen of doxorubicin." | ( Rapid and sensitive method for measuring the plasma concentration of doxorubicin and its metabolites. Kawanishi, T; Nanjo, K; Okuda, H; Sakai-Kato, K, 2012) | 0.38 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (17)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (17.65) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 6 (35.29) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.42
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.42) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (4.55%) | 5.53% |
| Reviews | 2 (9.09%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 19 (86.36%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||